Suppr超能文献

氟轻松植入剂治疗特发性视网膜血管炎、动脉瘤和神经视网膜炎综合征:一例报告

Fluocinolone Implant for Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome: A Case Report.

作者信息

Moreno-Castro Lucía, García-García Gerardo Pedro, Artaraz Joseba, Fonollosa Alex

机构信息

Department of Ophthalmology, Alicante University General Hospital, ISABIAL, Alicante, Spain.

Department of Ophthalmology, BioCruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain.

出版信息

Case Rep Ophthalmol. 2021 Sep 27;12(3):824-830. doi: 10.1159/000518011. eCollection 2021 Sep-Dec.

Abstract

Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare and progressive disorder that predominantly affects both the eyes of young female individuals and can threaten visual function. Peripheral ischemia and macular exudation are common findings in patients. The treatment options include panretinal photocoagulation (PRP), systemic immunosuppression, and intravitreal antiangiogenic and corticosteroid therapy. Fluocinolone acetonide intravitreal implant is approved for the treatment of nonanterior noninfectious uveitis and diabetic macular edema (ME), with an estimated therapeutic duration of 3 years. We describe a case of IRVAN syndrome in a child with ME who had been previously treated with PRP, antiangiogenic therapy, and several dexamethasone intravitreal implants and received a fluocinolone acetonide intravitreal implant in her right eye. The patient showed stabilization of the visual acuity and a marked reduction of the macular thickness 1 month after the treatment. At 12-month follow-up, the patient required perifoveal focal photocoagulation due to a rebound of the ME. After 2 years of follow-up, visual acuity remains stable and macular retinal thickening under control. Local long-standing steroid therapy has proved to be quite efficient in controlling the progression of the disease in our patient.

摘要

特发性视网膜血管炎、动脉瘤和神经视网膜炎(IRVAN)综合征是一种罕见的进行性疾病,主要影响年轻女性的双眼,可威胁视功能。外周缺血和黄斑渗出是患者的常见表现。治疗选择包括全视网膜光凝(PRP)、全身免疫抑制以及玻璃体内抗血管生成和皮质类固醇治疗。醋酸氟轻松玻璃体内植入物被批准用于治疗非前部非感染性葡萄膜炎和糖尿病性黄斑水肿(ME),估计治疗持续时间为3年。我们描述了一例患有ME的儿童IRVAN综合征病例,该患儿此前接受过PRP、抗血管生成治疗以及多次地塞米松玻璃体内植入,右眼接受了醋酸氟轻松玻璃体内植入物。治疗1个月后,患者视力稳定,黄斑厚度显著降低。在12个月的随访中,由于ME复发,患者需要进行黄斑中心凹周边局部光凝。经过2年的随访,视力保持稳定,黄斑视网膜增厚得到控制。局部长期使用类固醇治疗已证明在控制我们患者的疾病进展方面相当有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17eb/8543312/b27fa66017d7/cop-0012-0824-g01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验